K+ channel modulators for the treatment of neurological disorders and autoimmune diseases

Heike Wulff, Boris S. Zhorov

Research output: Contribution to journalArticle

145 Citations (Scopus)

Abstract

An overview of K+ channel pharmacology in general and a discussion of its medicinal chemistry which constitute targets for the treatment of neurological disorders, autoimmune diseases, and inflammation have been discussed. The discovery of K+ channel modulating drugs is increasingly assisted by structural information. Although currently, only KcsA and TBA are the only visualized example of a drug bound in the inner pore of a K+ channel, results of various mutational, electrophysiological, and ligand-binding experiments are increasingly interpreted in structural terms using homology modeling and ligand docking. It should be noted that the inner pore dimensions between the x ray structures of MthK, KvAP, and Kv1.2 vary widely. It is therefore advisable to interpret homology models of medicinally important K+ channels with caution. The huge diversity in the chemical structure of drugs modulating the same channel protein also poses as a challenge. Still, homology modeling and ligand docking are still popular methods in rationalizing huge and often controversial data on structure-activity relations of available ligands.

Original languageEnglish (US)
Pages (from-to)1744-1773
Number of pages30
JournalChemical Reviews
Volume108
Issue number5
DOIs
StatePublished - May 2008

Fingerprint

Modulators
Ligands
Pharmaceutical Preparations
X rays
Proteins
Experiments

ASJC Scopus subject areas

  • Chemistry(all)

Cite this

K+ channel modulators for the treatment of neurological disorders and autoimmune diseases. / Wulff, Heike; Zhorov, Boris S.

In: Chemical Reviews, Vol. 108, No. 5, 05.2008, p. 1744-1773.

Research output: Contribution to journalArticle

@article{d661f9b8c19241de8968f65599203f84,
title = "K+ channel modulators for the treatment of neurological disorders and autoimmune diseases",
abstract = "An overview of K+ channel pharmacology in general and a discussion of its medicinal chemistry which constitute targets for the treatment of neurological disorders, autoimmune diseases, and inflammation have been discussed. The discovery of K+ channel modulating drugs is increasingly assisted by structural information. Although currently, only KcsA and TBA are the only visualized example of a drug bound in the inner pore of a K+ channel, results of various mutational, electrophysiological, and ligand-binding experiments are increasingly interpreted in structural terms using homology modeling and ligand docking. It should be noted that the inner pore dimensions between the x ray structures of MthK, KvAP, and Kv1.2 vary widely. It is therefore advisable to interpret homology models of medicinally important K+ channels with caution. The huge diversity in the chemical structure of drugs modulating the same channel protein also poses as a challenge. Still, homology modeling and ligand docking are still popular methods in rationalizing huge and often controversial data on structure-activity relations of available ligands.",
author = "Heike Wulff and Zhorov, {Boris S.}",
year = "2008",
month = "5",
doi = "10.1021/cr078234p",
language = "English (US)",
volume = "108",
pages = "1744--1773",
journal = "Chemical Reviews",
issn = "0009-2665",
publisher = "American Chemical Society",
number = "5",

}

TY - JOUR

T1 - K+ channel modulators for the treatment of neurological disorders and autoimmune diseases

AU - Wulff, Heike

AU - Zhorov, Boris S.

PY - 2008/5

Y1 - 2008/5

N2 - An overview of K+ channel pharmacology in general and a discussion of its medicinal chemistry which constitute targets for the treatment of neurological disorders, autoimmune diseases, and inflammation have been discussed. The discovery of K+ channel modulating drugs is increasingly assisted by structural information. Although currently, only KcsA and TBA are the only visualized example of a drug bound in the inner pore of a K+ channel, results of various mutational, electrophysiological, and ligand-binding experiments are increasingly interpreted in structural terms using homology modeling and ligand docking. It should be noted that the inner pore dimensions between the x ray structures of MthK, KvAP, and Kv1.2 vary widely. It is therefore advisable to interpret homology models of medicinally important K+ channels with caution. The huge diversity in the chemical structure of drugs modulating the same channel protein also poses as a challenge. Still, homology modeling and ligand docking are still popular methods in rationalizing huge and often controversial data on structure-activity relations of available ligands.

AB - An overview of K+ channel pharmacology in general and a discussion of its medicinal chemistry which constitute targets for the treatment of neurological disorders, autoimmune diseases, and inflammation have been discussed. The discovery of K+ channel modulating drugs is increasingly assisted by structural information. Although currently, only KcsA and TBA are the only visualized example of a drug bound in the inner pore of a K+ channel, results of various mutational, electrophysiological, and ligand-binding experiments are increasingly interpreted in structural terms using homology modeling and ligand docking. It should be noted that the inner pore dimensions between the x ray structures of MthK, KvAP, and Kv1.2 vary widely. It is therefore advisable to interpret homology models of medicinally important K+ channels with caution. The huge diversity in the chemical structure of drugs modulating the same channel protein also poses as a challenge. Still, homology modeling and ligand docking are still popular methods in rationalizing huge and often controversial data on structure-activity relations of available ligands.

UR - http://www.scopus.com/inward/record.url?scp=44849093511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44849093511&partnerID=8YFLogxK

U2 - 10.1021/cr078234p

DO - 10.1021/cr078234p

M3 - Article

C2 - 18476673

AN - SCOPUS:44849093511

VL - 108

SP - 1744

EP - 1773

JO - Chemical Reviews

JF - Chemical Reviews

SN - 0009-2665

IS - 5

ER -